Cooper ME - Search Results

1

Serum lipids and the progression of nephropathy in type 1 diabetes.

Thomas MC, Rosengård-Bärlund M, Mills V, Rönnback M, Thomas S, Forsblom C, Cooper ME, Taskinen MR, Viberti G, Groop PH. Thomas MC, et al. Among authors: cooper me. Diabetes Care. 2006 Feb;29(2):317-22. doi: 10.2337/diacare.29.02.06.dc05-0809. Diabetes Care. 2006. PMID: 16443880 Free article.

2

Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat.

Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Soulis-Liparota T, et al. Diabetes. 1991 Oct;40(10):1328-34. doi: 10.2337/diab.40.10.1328. Diabetes. 1991. PMID: 1834497

3

Hypertension and diabetes.

Jandeleit-Dahm K, Cooper ME. Jandeleit-Dahm K, et al. Among authors: cooper me. Curr Opin Nephrol Hypertens. 2002 Mar;11(2):221-8. doi: 10.1097/00041552-200203000-00014. Curr Opin Nephrol Hypertens. 2002. PMID: 11856916 Review.

4

A low-sodium diet potentiates the effects of losartan in type 2 diabetes.

Houlihan CA, Allen TJ, Baxter AL, Panangiotopoulos S, Casley DJ, Cooper ME, Jerums G. Houlihan CA, et al. Among authors: cooper me. Diabetes Care. 2002 Apr;25(4):663-71. doi: 10.2337/diacare.25.4.663. Diabetes Care. 2002. PMID: 11919122 Clinical Trial.

5

Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction.

Houlihan CA, Akdeniz A, Tsalamandris C, Cooper ME, Jerums G, Gilbert RE. Houlihan CA, et al. Among authors: cooper me. Diabetes Care. 2002 Jun;25(6):1072-7. doi: 10.2337/diacare.25.6.1072. Diabetes Care. 2002. PMID: 12032117 Clinical Trial.

6

Turning up the heat: heat shock proteins, hypertension and cardiovascular risk.

Thomas MC, Cooper ME. Thomas MC, et al. Among authors: cooper me. J Hypertens. 2002 Sep;20(9):1713-4. doi: 10.1097/00004872-200209000-00010. J Hypertens. 2002. PMID: 12195107 No abstract available.

7

Role of nephrin in renal disease including diabetic nephropathy.

Cooper ME, Mundel P, Boner G. Cooper ME, et al. Semin Nephrol. 2002 Sep;22(5):393-8. doi: 10.1053/snep.2002.34724. Semin Nephrol. 2002. PMID: 12224046 Review.

8

Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy.

Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrell LM, Jerums G, Osicka TM. Forbes JM, et al. Among authors: cooper me. Diabetes. 2002 Nov;51(11):3274-82. doi: 10.2337/diabetes.51.11.3274. Diabetes. 2002. PMID: 12401719

9

ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat.

Wilkinson-Berka JL, Kelly DJ, Koerner SM, Jaworski K, Davis B, Thallas V, Cooper ME. Wilkinson-Berka JL, et al. Among authors: cooper me. Diabetes. 2002 Nov;51(11):3283-9. doi: 10.2337/diabetes.51.11.3283. Diabetes. 2002. PMID: 12401720

10

Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.

Davis BJ, Cao Z, de Gasparo M, Kawachi H, Cooper ME, Allen TJ. Davis BJ, et al. Among authors: cooper me. J Hypertens. 2003 Jan;21(1):209-16. doi: 10.1097/00004872-200301000-00031. J Hypertens. 2003. PMID: 12544453

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

716 results

Search Page

Filters